Anti-CD324 monoclonal antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-10087258-B2
Application number	US-201615352883-A
Country	US
Kind code	B2
Filing date	Nov 16, 2016
Priority date	Feb 8, 2012
Publication date	Oct 2, 2018
Grant date	Oct 2, 2018

Abstract

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.

First claim

The invention claimed is:

1. A method of treating a CD324-associated neoplastic disorder in a subject comprising administering an isolated anti-CD324 antibody or an antigen-binding fragment thereof to the subject, wherein the isolated anti-CD324 antibody or antigen-binding fragment thereof is selected from the group consisting of:
a) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 20 for CDR-L1, residues 50-56 of SEQ ID NO: 20 for CDR-L2, and residues 89-97 of SEQ ID NO: 20 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 21 for CDR-H1, residues 50-65 of SEQ ID NO: 21 for CDR-H2 and 95-102 of SEQ ID NO: 21 for CDR-H3, wherein the residues are numbered according to Kabat;
b) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 22 for CDR-L1, residues 50-56 of SEQ ID NO: 22 for CDR-L2, and residues 89-97 of SEQ ID NO: 22 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 23 for CDR-H1, residues 50-65 of SEQ ID NO: 23 for CDR-H2 and residues 95-102 of SEQ ID NO: 23 for CDR-H3, wherein the residues are numbered according to Kabat;
c) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 24 for CDR-L1, residues 50-56 of SEQ ID NO: 24 for CDR-L2, and residues 89-97 of SEQ ID NO: 24 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 25 for CDR-H1, residues 50-65 of SEQ ID NO: 25 or SEQ ID NO: 73 for CDR-H2 and residues 95-102 of SEQ ID NO: 25 for CDR-H3, wherein the residues are numbered according to Kabat;
d) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 26 for CDR-L1, residues 50-56 of SEQ ID NO: 26 for CDR-L2, and residues 89-97 of SEQ ID NO: 26 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 27 for CDR-H1, residues 50-65 of SEQ ID NO: 27 for CDR-H2 and residues 95-102 of SEQ ID NO: 27 for CDR-H3, wherein the residues are numbered according to Kabat;
e) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 28 for CDR-L1, residues 50-56 of SEQ ID NO: 28 for CDR-L2, and residues 89-97 of SEQ ID NO: 28 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 29 for CDR-H1, residues 50-65 of SEQ ID NO: 29 for CDR-H2 and residues 95-102 of SEQ ID NO: 29 for CDR-H3, wherein the residues are numbered according to Kabat;
f) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 30 for CDR-L1, residues 50-56 of SEQ ID NO: 30 for CDR-L2, and residues 89-97 of SEQ ID NO: 30 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 31 for CDR-H1, residues 50-65 of SEQ ID NO: 31 for CDR-H2 and residues 95-102 of SEQ ID NO: 31 for CDR-H3, wherein the residues are numbered according to Kabat;
g) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 32 for CDR-L1, residues 50-56 of SEQ ID NO: 32 for CDR-L2, and residues 89-97 of SEQ ID NO: 32 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 33 for CDR-H1, residues 50-65 of SEQ ID NO: 33 for CDR-H2 and residues 95-102 of SEQ ID NO: 33 for CDR-H3, wherein the residues are numbered according to Kabat;
h) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 34 for CDR-L1, residues 50-56 of SEQ ID NO: 34 for CDR-L2, and residues 89-97 of SEQ ID NO: 34 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 35 for CDR-H1, residues 50-65 of SEQ ID NO: 35 for CDR-H2 and residues 95-102 of SEQ ID NO: 35 for CDR-H3, wherein the residues are numbered according to Kabat;
i) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 36 for CDR-L1, residues 50-56 of SEQ ID NO: 36 for CDR-L2, and residues 89-97 of SEQ ID NO: 36 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 37 for CDR-H1, residues 50-65 of SEQ ID NO: 37 for CDR-H2 and residues 95-102 of SEQ ID NO: 37 for CDR-H3, wherein the residues are numbered according to Kabat;
j) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 38 for CDR-L1, residues 50-56 of SEQ ID NO: 38 for CDR-L2, and residues 89-97 of SEQ ID NO: 38 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 39 for CDR-H1, residues 50-65 of SEQ ID NO: 39 for CDR-H2 and residues 95-102 of SEQ ID NO: 39 for CDR-H3, wherein the residues are numbered according to Kabat;
k) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 40 for CDR-L1, residues 50-56 of SEQ ID NO: 40 for CDR-L2, and residues 89-97 of SEQ ID NO: 40 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 41 for CDR-H1, residues 50-65 of SEQ ID NO: 41 for CDR-H2 and residues 95-102 of SEQ ID NO: 41 for CDR-H3, wherein the residues are numbered according to Kabat;
l) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 42 for CDR-L1, residues 50-56 of SEQ ID NO: 42 for CDR-L2, and residues 89-97 of SEQ ID NO: 42 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 43 for CDR-H1, residues 50-65 of SEQ ID NO: 43 for CDR-H2 and residues 95-102 of SEQ ID NO: 43 for CDR-H3, wherein the residues are numbered according to Kabat;
m) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 44 for CDR-L1, residues 50-56 of SEQ ID NO: 44 for CDR-L2, and residues 89-97 of SEQ ID NO: 44 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 45 for CDR-H1, residues 50-65 of SEQ ID NO: 45 for CDR-H2 and residues 95-102 of SEQ ID NO: 45 for CDR-H3, wherein the residues are numbered according to Kabat;
n) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 46 for CDR-L1, residues 50-56 of SEQ ID NO: 46 for CDR-L2, and residues 89-97 of SEQ ID NO: 46 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 47 for CDR-H1, residues 50-65 of SEQ ID NO: 47 for CDR-H2 and residues 95-102 of SEQ ID NO: 47 for CDR-H3, wherein the residues are numbered according to Kabat;
o) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 48 for CDR-L1, residues 50-56 of SEQ ID NO: 48 for CDR-L2, and residues 89-97 of SEQ ID NO: 48 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 49 for CDR-H1, residues 50-65 of SEQ ID NO: 49 for CDR-H2 and residues 95-102 of SEQ ID NO: 49 for CDR-H3, wherein the residues are numbered according to Kabat;
p) an antibody comprising three light chain complementarity determining regions set forth as residu

Assignees

• Abbvie Stemcentrx Llc

Inventors

• Stull Robert A
• Aujay Monette
• Foord Orit
• Bankovich Alex
• Hampl Johannes
• Dylla Scott J
• Liu David

Classifications

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K16/2896 Primary

  against molecules with a "CD"-designation, not provided for elsewhere · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title